Joseph Kim, Inovio CEO (Andrew Harnik, AP Images)

Covid-19 roundup: In­ovio en­lists plas­mid man­u­fac­tur­er to re­place the one it's in le­gal feud with; Cy­ber­at­tacks spot­ted tar­get­ing vac­cine dis­tri­b­u­tion 

With its Phase II tri­al fi­nal­ly un­der­way, In­ovio has en­list­ed an­oth­er key man­u­fac­tur­ing part­ner to hit its goal of hun­dreds of mil­lions of dos­es of its DNA vac­cine — fill­ing the role of a con­tract man­u­fac­tur­er it’s still in a le­gal stand­off with.

Japan’s Kane­ka Eu­ro­gen­tec is tasked with plas­mid pro­duc­tion, for which In­ovio has pre­vi­ous­ly re­lied on Ko­re­an-owned VGXI. It joins a con­sor­tium In­ovio has as­sem­bled that in­cludes Ther­mo Fish­er Sci­en­tif­ic, Richter-Helm Bi­o­Log­ics and Ol­o­gy Bioser­vices.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.